407 related articles for article (PubMed ID: 6214358)
1. A clinical comparison of MDP and DMAD.
Rosenthall L; Stern J; Arzoumanian A
Clin Nucl Med; 1982 Sep; 7(9):403-6. PubMed ID: 6214358
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 99Tcm-labelled MDP and DMAD bone scanning agents in patients with advanced breast cancer.
Coleman RE; Meier CA; Rubens RD; Fogelman I
Nucl Med Commun; 1988 Jul; 9(7):481-5. PubMed ID: 3173907
[TBL] [Abstract][Full Text] [Related]
3. New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate.
Subramanian G; McAfee JG; Thomas FD; Feld TA; Zapf-Longo C; Palladino E
Radiology; 1983 Dec; 149(3):823-8. PubMed ID: 6316414
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of a technetium-99m bone imaging agent based on the vicinal diphosphonate 1,2-diphosphonoethyleneglycol (DPEG).
Pauwels EK; Camps JA; Blom J; Hermans J; Kelly JD; Cumming SA; Blackburn GM; Rashid A
Nucl Med Commun; 1985 Nov; 6(11):739-45. PubMed ID: 3831848
[TBL] [Abstract][Full Text] [Related]
5. A comparison of bone imaging with Tc-99m DPD and Tc-99m MDP: concise communication.
Buell U; Kleinhans E; Zorn-Bopp E; Reuschel W; Muenzing W; Moser EA; Seiderer M
J Nucl Med; 1982 Mar; 23(3):214-7. PubMed ID: 6460854
[TBL] [Abstract][Full Text] [Related]
6. Technetium-99m complexes of dimethylaminomethylene diphosphonate (DMAD)--II. Biological distributions of 99mTc-DMAD components isolated by anion exchange HPLC.
Holland ME; Bugaj J; Heineman WR; Deutsch E
Int J Rad Appl Instrum B; 1989; 16(3):313-7. PubMed ID: 2497091
[TBL] [Abstract][Full Text] [Related]
7. 99Tcm-MDP and 99Tcm-DPD in pathologic bone lesions. A visual and quantitative comparison.
Lantto T; Vorne M; Mokka R; Vähätalo S
Acta Radiol; 1987; 28(5):631-3. PubMed ID: 2960361
[TBL] [Abstract][Full Text] [Related]
8. Technetium-99m MDP vs technetium-99m dicarboxypropane diphosphonate. A clinical comparison in various pathologic conditions.
Godart G; Durez M; Bevilacqua M; Abramovici J; Robience Y
Clin Nucl Med; 1986 Feb; 11(2):92-7. PubMed ID: 3769350
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the performance and interpretation of bone scans.
Muroff LR
Clin Nucl Med; 1981 Oct; 6(10S):P68-76. PubMed ID: 6271444
[No Abstract] [Full Text] [Related]
10. Improved lesion detection with dimethyl-amino-diphosphonate: a report of two cases.
Smith ML; Martin W; McKillop JH; Fogelman I
Eur J Nucl Med; 1984; 9(11):519-20. PubMed ID: 6240401
[TBL] [Abstract][Full Text] [Related]
11. Adverse allergic reaction to technetium-99m methylene diphosphonate.
Spicer JA; Preston DF; Stephens RL
J Nucl Med; 1985 Apr; 26(4):373-4. PubMed ID: 2984362
[TBL] [Abstract][Full Text] [Related]
12. [Bone scintigraphy with 99mTc-hydroxymethylene diphosphonate (HMDP)--comparison with 99mtc-MDP (author's transl)].
Nakano S; Hasegawa Y; Shiomura K; Ibuka K; Hashizume T
Kaku Igaku; 1981 Dec; 18(10):1485-8. PubMed ID: 6210789
[No Abstract] [Full Text] [Related]
13. A comparison between the diagnostic efficacy of 99mTc-MDP, 99mTc-DPD and 99mTc-HDP for the detection of bone metastases.
Pauwels EK; Blom J; Camps JA; Hermans J; Rijke AM
Eur J Nucl Med; 1983; 8(3):118-22. PubMed ID: 6220908
[TBL] [Abstract][Full Text] [Related]
14. Which diphosphonate for routine bone scintigraphy (MDP, HDP or DPD)?
Frühling J; Verbist A; Balikdjian D
Nucl Med Commun; 1986 Jun; 7(6):415-25. PubMed ID: 3748485
[TBL] [Abstract][Full Text] [Related]
15. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. II. Comparison of Tc-99m hydroxymethylene diphosphonate (HMDP) with other technetium-labeled bone-imaging agents in a canine model.
Bevan JA; Tofe AJ; Benedict JJ; Francis MD; Barnett BL
J Nucl Med; 1980 Oct; 21(10):967-70. PubMed ID: 6252299
[TBL] [Abstract][Full Text] [Related]
16. Skeletal scintigraphy with technetium diphosphonate in multiple myeloma--a comparison with skeletal x-ray.
Lindström E; Lindström FD
Acta Med Scand; 1980; 208(4):289-91. PubMed ID: 6449830
[TBL] [Abstract][Full Text] [Related]
17. Relative lesion detection ability of Tc-99m HMDP and Tc-99m MDP: concise communication.
Van Duzee BF; Schaefer JA; Ball JD; Chilton HM; Cowan RJ; Kuni C; Trow R; Watson NE
J Nucl Med; 1984 Feb; 25(2):166-9. PubMed ID: 6233404
[TBL] [Abstract][Full Text] [Related]
18. A clinical comparison of 99mTc-DPD and two 99mTc-MDP agents.
Vorne M; Vähätalo S; Lantto T
Eur J Nucl Med; 1983; 8(9):395-7. PubMed ID: 6226527
[TBL] [Abstract][Full Text] [Related]
19. Determination of lesion to normal bone uptake ratios of skeletal radiopharmaceuticals by QARG (quantitative autoradiography).
Ghiron J; Volkert WA; Garlich J; Holmes RA
Int J Rad Appl Instrum B; 1991; 18(2):235-40. PubMed ID: 2026500
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of 99mTc-hydroxymethylene diphosphonate (HMDP) bone scintigraphy: comparison with 99mTc-MDP (author's transl)].
Honda H; Oshiumi Y; Kamoi I; Ichiya Y; Wada M; Matsuura K
Kaku Igaku; 1981 Nov; 18(9):1315-9. PubMed ID: 6461790
[No Abstract] [Full Text] [Related]
[Next] [New Search]
